BioAge Labs (BIOA) Receivables (2025 - 2026)
BioAge Labs (BIOA) reported Receivables of $709000.0 for Q1 2026, up 96.4% on a YoY basis from $361000.0 in Q1 2025, and down 7.8% sequentially from $769000.0 in Q4 2025.
BioAge Labs (BIOA) Receivables (2025 - 2026) Analysis & Trends
BioAge Labs (BIOA) has 2 years of Receivables data on file, last reported at $709000.0 in Q1 2026.
- For the quarter ending Q1 2026, Receivables rose 96.4% year-over-year to $709000.0; the trailing twelve-month figure through Mar 2026 stood at $709000.0 (up 96.4% YoY), and the FY2025 full-year result was $769000.0, changed N/A from the prior year.
- Receivables retreated to $709000.0 in Q1 2026, from $769000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $769000.0 in Q4 2025 to a low of $361000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 2.99 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 6.46 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 312.00 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.29 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.58 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 768.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.15 Bn |
| 10 | BioAge Labs | 930.32 Mn | 930.32 Mn | -10.37 Mn | 709,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 709,000.00 |
| Dec 31, 2025 | 769,000.00 |
| Sep 30, 2025 | 515,000.00 |
| Jun 30, 2025 | 603,000.00 |
| Mar 31, 2025 | 361,000.00 |